Deferiprone as Parkinson's disease modifier: quantification of 3-O-methyldopa/l-dopa plasmatic ratio in patients

被引：0
|
作者：
Charbonnier-Beaupel, F. [1 ]
Bihan, K. [1 ]
Zahr, N. [1 ]
Corvol, J. C. [1 ]
Devos, D. [2 ]
机构：
[1] Pitie Salpetriere, Paris, France
[2] CHU Lille, F-59037 Lille, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2013年 / 27卷
关键词：
Parkinson's disease; deferiprone; disease modifier; metabolic ratio;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：73 / 74
页数：2
相关论文
共 50 条
  • [41] Does L-dopa treatment contribute to reduction in body weight in elderly patients with Parkinson's disease?
    Pålhagen, S
    Lorefält, B
    Carlsson, M
    Ganowiak, W
    Toss, G
    Unosson, M
    Granérus, AK
    ACTA NEUROLOGICA SCANDINAVICA, 2005, 111 (01): : 12 - 20
  • [42] Hyperhomocysteinemia in L-Dopa Treated Patients with Parkinson's Disease: Potential Implications in Cognitive Dysfunction and Dementia?
    Zoccolella, S.
    Lamberti, S. V.
    Iliceto, G.
    Santamato, A.
    Lamberti, P.
    Logroscino, G.
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (28) : 3253 - 3261
  • [43] The relation of serum uric acid levels with L-Dopa treatment and progression in patients with Parkinson's disease
    Vieru, Eugeniu
    Koksal, Ayhan
    Mutluay, Belgin
    Dirican, Ayten Ceyhan
    Altunkaynak, Yavuz
    Baybas, Sevim
    NEUROLOGICAL SCIENCES, 2016, 37 (05) : 743 - 747
  • [44] L-Dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson's disease
    Isobe, Chiaki
    Abe, Takashi
    Terayama, Yasuo
    JOURNAL OF CLINICAL NEUROSCIENCE, 2010, 17 (06) : 717 - 721
  • [45] Impact of L-DOPA treatment of patients with Parkinson's disease on mononuclear subsets and phagocytosis in the peripheral blood
    Hurny, Artur
    Michalowska-Wender, Grazyna
    Wender, Mieczyslaw
    FOLIA NEUROPATHOLOGICA, 2013, 51 (02) : 127 - 131
  • [46] Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease
    Devos, David
    Lejeune, Stephanie
    Cormier-Dequaire, Florence
    Tahiri, Khadija
    Charbonnier-Beaupel, Fanny
    Rouaix, Nathalie
    Duhamel, Alain
    Sablonniere, Bernard
    Bonnet, Anne-Marie
    Bonnet, Cecilia
    Zahr, Noel
    Costentin, Jean
    Vidailhet, Marie
    Corvol, Jean-Christophe
    PARKINSONISM & RELATED DISORDERS, 2014, 20 (02) : 170 - 175
  • [47] Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy
    Mazzella, L
    Yahr, MD
    Marinelli, L
    Huang, N
    Moshier, E
    Di Roccoa, A
    PARKINSONISM & RELATED DISORDERS, 2005, 11 (03) : 151 - 155
  • [48] The relation of serum uric acid levels with l-Dopa treatment and progression in patients with Parkinson’s disease
    Eugeniu Vieru
    Ayhan Köksal
    Belgin Mutluay
    Ayten Ceyhan Dirican
    Yavuz Altunkaynak
    Sevim Baybas
    Neurological Sciences, 2016, 37 : 743 - 747
  • [49] Work and power reduced in L-dopa naive patients in the early-stages of Parkinson's disease
    Lima, Lidiane Oliveira
    Cardoso, Francisco
    Teixeira-Salmela, Luci Fuscaldi
    Rodrigues-de-Paula, Fatima
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2016, 74 (04) : 287 - 292
  • [50] L-Dopa decreases cutaneous nociceptive inhibition of motor activity in Parkinson's disease
    Serrao, M
    Parisi, L
    Valente, G
    Martini, A
    Fattapposta, F
    Pierelli, F
    Rossi, P
    ACTA NEUROLOGICA SCANDINAVICA, 2002, 105 (03): : 196 - 201
12345